A clinically detailed review of enclomiphene citrate withdrawal and discontinuation syndrome, covering hormonal rebound, adverse events from trials and FAERS data, and evidence-based management strategies.
A breakdown of Epitalon (epitalon tetrapeptide) adverse events, withdrawal risk, discontinuation data, and what to expect when stopping the peptide.
A comprehensive clinical guide to delayed-onset side effects of oral estradiol, covering when symptoms appear, the underlying mechanisms, trial data, and how to monitor and manage each risk over time.
A guide to oral estradiol withdrawal and discontinuation syndrome, covering symptoms, timelines, mechanisms, risk factors, and evidence-based tapering strategies.
A guide to delayed-onset side effects of Repatha (evolocumab), covering injection-site reactions, neurocognitive effects, musculoskeletal complaints, diabetes risk, and post-market FAERS data with primary-source citations.
A clinical review of finasteride's delayed-onset adverse effects, including post-finasteride syndrome, persistent sexual dysfunction, depression, and cognitive changes, with trial data, FAERS reports, and prescribing guidance.
A data-driven breakdown of finasteride adverse event rates from PLESS, PCPT, MTOPS, and FDA FAERS reports, with direct trial statistics and clinical context.
A look at Addyi (flibanserin) side effects, including rare and potentially lasting adverse events, drawn from clinical trials, FDA labeling, and FAERS post-market data.
A breakdown of GHK-Cu (copper tripeptide) side effects, including rare adverse events, permanent risk signals, and what the published evidence actually shows.
Leqvio's long-term side effects are mostly mild injection-site reactions (8.2%); serious events match placebo, except in severe renal or hepatic impairment.
A clinical deep-dive into the rare but serious adverse events of Tresiba (insulin degludec), including severe hypoglycemia, anaphylaxis, hypokalemia, and heart failure risk, with trial data, FAERS signals, and prescriber guidance.
A data-driven breakdown of isotretinoin adverse event rates drawn from key clinical trials, the FDA label, FAERS reports, and post-market literature. prepared by the HealthRX.com Editorial Team.
A comprehensive guide to isotretinoin adverse events, withdrawal and discontinuation phenomena, rare side effects, and post-course management, with primary citations from PubMed, FDA, and clinical trial data.
A clinical review of Jatenzo (oral testosterone undecanoate) side effects, including potentially permanent risks such as cardiovascular changes, polycythemia, and fertility loss. prepared by the HealthRX.com Editorial Team.
What happens when you stop Jatenzo (oral testosterone undecanoate)? This clinically detailed guide covers withdrawal symptoms, timelines, FAERS data, and management strategies.
Weight gain wasn't a distinct adverse event in Dayvigo trials; somnolence was most common, at 10% (5mg) to 22% (10mg). See full incidence data by dose.
A guide to liothyronine (Cytomel) withdrawal and discontinuation syndrome, covering symptoms, timeline, risk factors, and safe tapering protocols backed by primary sources.
A guide to liraglutide's potentially permanent side effects, covering thyroid tumors, pancreatitis, gallbladder disease, kidney injury, and more, with trial data, FDA label warnings, and clinical management guidance.
A guide to liraglutide withdrawal and discontinuation syndrome, covering rebound weight gain, blood sugar changes, GI symptoms, and how to stop liraglutide safely.
Yes, rare hepatocellular injury has been reported with losartan. Learn ALT thresholds, warning signs, and when to stop the drug immediately.
Does stopping losartan cause a withdrawal syndrome? Learn what the evidence says about rebound hypertension, discontinuation effects, and how to safely taper losartan with physician guidance.
A thorough clinical review of low-dose naltrexone (LDN) side effects, including rare and potentially long-lasting adverse events, with citations from trials, FAERS data, and post-market literature.
FDA-based trial data links cough to 2.25% of metformin users, alongside GI effects in 20-53% and B12 deficiency risk after long-term use.
A guide to metformin's potentially permanent side effects, including B12 deficiency, lactic acidosis risk, and long-term kidney considerations, with cited trial data and dosing guidance.
A guide to the rare but serious adverse events linked to metformin, including lactic acidosis, vitamin B12 deficiency, severe hypoglycemia, and hepatotoxicity. Includes trial data, FAERS reports, and clinical thresholds.
A clinical breakdown of metformin adverse events by severity grade, organ system, and patient phenotype, with data from UKPDS, FAERS, and post-market literature to guide prescribing decisions.
A clinically detailed guide to delayed-onset side effects of MK-677 (ibutamoren), covering insulin resistance, edema, cortisol changes, and long-term safety signals from published trials and FAERS data.
A clinical breakdown of MOTS-c adverse events by severity grade and patient phenotype, covering injection-site reactions, metabolic shifts, and immune responses. prepared by the HealthRX.com Editorial Team.
A guide to MOTS-c adverse events, what happens when you stop the peptide, whether a true withdrawal syndrome exists, and how to discontinue safely based on current preclinical and emerging human data.
A breakdown of NMN and NR adverse event rates from published human trials, FAERS reports, and post-market literature. Learn which side effects are common, which are rare, and what doses produced them.
A breakdown of NMN and NR (nicotinamide mononucleotide/riboside) side effects, including rare adverse events, potentially permanent risks, and what current human trial data actually show.
What clinical trials, the FDA label, and post-market surveillance actually show about oral micronized progesterone (Prometrium) side effects, with an honest accounting of which numbers are well established and which need primary-source verification.
A clinical deep-dive into oral micronized progesterone (Prometrium) adverse events, ranked by severity and stratified by patient phenotype, with trial data, FAERS analysis, and dosing context.
An evidence-based look at oral micronized progesterone (Prometrium) discontinuation symptoms: what is established about the underlying mechanism, what is plausible but unproven in humans, and how clinicians typically approach tapering.
Oral minoxidil's documented delayed effects are hypertrichosis, fluid retention, and tachycardia by weeks 8 to 24; menstrual changes are not a confirmed effect.
A guide to oral minoxidil's potentially permanent side effects, including pericardial effusion, hypertrichosis, and cardiac remodeling, with trial data, FAERS reports, and clinical guidance.
A guide to the rare but serious adverse events of oral minoxidil, including pericardial effusion, cardiac decompensation, and severe fluid retention, with trial data, FDA labeling, and FAERS signals.
A clinical breakdown of oral minoxidil adverse events by severity and patient phenotype, covering fluid retention, hypertrichosis, cardiovascular risk, and which patients face the highest burden.
A clinical review of what happens when low-dose oral minoxidil is stopped abruptly, including rebound hair loss timelines, cardiovascular rebound risk, fluid shifts, and how to taper safely. prepared by the HealthRX.com Editorial Team.
A guide to the rare but serious adverse events associated with Ozempic (semaglutide 0.5 to 2.0 mg), including pancreatitis, thyroid tumors, gastroparesis, vision changes, and suicidality signals, with trial data, FDA labeling, and FAERS reporting.
A clinical breakdown of Prometrium (micronized progesterone) adverse event rates from key trials, FDA labeling, FAERS data, and post-marketing surveillance. prepared by the HealthRX.com Editorial Team.
A guide to Prometrium (micronized progesterone) withdrawal and discontinuation syndrome, covering symptoms, timelines, FAERS data, and tapering strategies backed by primary-source evidence.
A data-driven breakdown of PT-141 (bremelanotide) adverse event incidence rates from FDA key trials, FAERS reports, and post-market literature, with real percentages and clinical context.
A guide to rapamycin (sirolimus) side effects, with a focus on potentially permanent adverse events, real trial data, FDA label warnings, and clinical decision guidance.
A breakdown of rapamycin (sirolimus) adverse events by severity grade and patient phenotype, drawing on FDA labeling, FAERS data, and key transplant and longevity trials.
A deep look at what happens when rapamycin (sirolimus) is stopped abruptly or tapered, including rebound immunologic activity, graft rejection risk, mTOR reactivation, and practical discontinuation protocols backed by primary-source evidence.
Crestor rarely causes rhabdomyolysis, liver injury, diabetes, myopathy, or lung disease. Learn early warning signs and risk factors to catch them in time.
Does stopping rosuvastatin (Crestor) cause withdrawal symptoms? Learn what the evidence says about discontinuation syndrome, rebound effects, muscle pain, and how to safely taper or stop statins.
A guide to Rybelsus (oral semaglutide) side effects that may be long-lasting or permanent, including thyroid tumors, pancreatitis, gastroparesis, vision changes, and kidney injury, with trial data, FDA labeling, and FAERS reports.
A guide to Saxenda (liraglutide 3 mg) delayed-onset side effects, covering gastrointestinal, pancreatic, thyroid, gallbladder, and psychiatric adverse events with trial data, FAERS signals, and practical management guidance.
What happens when you stop Saxenda (liraglutide 3 mg)? Learn about withdrawal symptoms, weight regain, GI rebound, and evidence-based tapering strategies reviewed by HealthRX.com physicians.
A clinical breakdown of sermorelin adverse events, including injection-site reactions, hormonal effects, and rare safety signals, with trial-level incidence data and FDA label analysis.
A guide to sermorelin withdrawal and discontinuation syndrome, covering what happens when you stop, how long symptoms last, and how to taper safely. Includes trial data, FAERS signals, and FDA labeling.
A data-driven breakdown of sildenafil side effect incidence rates from key trials, FDA labeling, FAERS, and post-market literature, with dose-specific comparisons for 20 mg to 100 mg.
A comprehensive, evidence-based review of rare but serious adverse events associated with sildenafil 20 to 100 mg, including NAION, priapism, sudden hearing loss, severe hypotension, and Stevens-Johnson Syndrome, with primary-source citations and clinical guidance.
A clinical deep-dive into spironolactone's delayed-onset side effects for acne treatment, including hyperkalemia, menstrual disruption, breast changes, and kidney effects. Backed by trial data, FDA labeling, and FAERS reports.
A guide to which spironolactone side effects are reversible versus potentially permanent, covering gynecomastia, electrolyte and renal effects, and hormonal changes, with an honest account of where the evidence is strong and where specific numbers require verification.
A clinical breakdown of spironolactone adverse events by severity grade and patient phenotype, including data from FAERS, randomized trials, and dermatology cohorts. Reviewed by board-certified physicians.
A guide to tadalafil's rare but potentially lasting adverse effects, including NAION, priapism, hearing loss, and serotonin interactions, with data from FDA labeling, FAERS, and published trials.
A clinical review of TB-500 (thymosin beta-4 active fragment) adverse event rates drawn from human trials, FAERS reports, and post-market literature. prepared by the HealthRX.com Editorial Team.